BNP/PUT/ELI LILLY & CO/800/0.1/20.09.24 Stock

DE000PC7ZH87

Real-time Boerse Frankfurt Warrants 05:21:09 2024-06-27 EDT
1.17 ^EUR	-7.87%

Current month	-67.27%
1 month	-69.69%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ELI LILLY AND COMPANY

Chart BNP/PUT/ELI LILLY & CO/800/0.1/20.09.24

Latest news about ELI LILLY AND COMPANY

Augustine Therapeutics N.V. announced that it expects to receive funding from a group of investors	06-25	CI
Top Midday Stories: Microsoft Hit with EU Antitrust Charges; Judge Blocks Swipe-Fee Settlement Between Visa, Mastercard and Retailers; Novo Nordisk Secures Chinese Approval for Weight-Loss Drug; Tesla, Ford Issue Recalls	06-25	MT
Eli Lilly Working With OpenAI to Develop Medicines Against Drug-Resistant Pathogens	06-25	DJ
Eli Lilly Teams Up With OpenAI to Develop Antimicrobials for Drug-Resistant Bacteria	06-25	MT

More news

Quotes 5-day view

Date	Price	Change
24-06-27	1.17	-7.87%
24-06-26	1.27	+1.60%
24-06-25	1.25	-8.76%
24-06-24	1.37	-15.95%
24-06-21	1.63	-4.68%

Real-time Boerse Frankfurt Warrants

Last update June 27, 2024 at 05:21 am

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	ELI LILLY AND COMPANY
Issuer	BNP Paribas
WKN	PC7ZH8
ISIN	DE000PC7ZH87
Date issued	2024-04-09
Strike	800 $
Maturity	2024-09-20 (86 Days)
Parity	10 : 1
Emission price	6.45 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Highest since issue	9.66 €
Lowest since issue	1.11 €
Delta	-0.17x
Omega	11.87
Premium	12.68x
Gearing	69.4x
Moneyness	0.8876
Difference Strike	-101.3 $
Difference Strike %	-12.66%
Spread	0.03 €
Spread %	2.44%
Theoretical value	1.185
Implied Volatility	30.19 %
Total Loss Probability	79.40 %
Intrinsic value	0.000000
Present value	1.185
Break even	787.32 €
Theta	-0.12x
Vega	0.1x
Rho	-0.03x

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Sector

More about the company